As a potential immune checkpoint gene, CEBPB was not only associated with the progression of triple-negative breast cancer[30] but also promoted the occurrence and drug resistance of gastric cancer[33] and ovarian cancer,[34] and played a role in the progression of PCa.[35] Similarly to the aforementioned results, our current study had also revealed that CEBPB could participate in the occurrence and development of UM through the immune pathway, leading to lower survival rates in patients with UM. The gene discussed is CEBPB; the disease is ovarian carcinoma.